TIDMORPH

Open Orphan PLC

07 February 2020

07 February 2020

RNS REACH

Open Orphan Plc

("Open Orphan" or the "Company")

Investor Event Attendance and Presentation

Open Orphan presents at Shares Growth and Invention Forum, London

Open Orphan, the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, is pleased to announce that the Company will be attending and presenting at the Shares Growth and Invention Forum on February 11, 2020 at Business Design Centre, London N1, London, N1 0QH. Cathal will be presenting at 15:30 in the Babbage Room. Investors are able to register to attend at https://ajbell.eventsair.com/gif-2020/private/Site/Register.

Cathal Friel, Open Orphan's Executive Chairman will be presenting from 15:30 onwards to update existing and potential investors on the Company's business plans for 2020.

The event will provide an opportunity for investors to hear about the progress being made by the Company following the acquisition of hVIVO and the potential for Open Orphan as it moves rapidly forward. hVIVO, is a world leader in the provision of viral challenge studies, vaccine and viral laboratory services, supporting product development for customers developing antivirals, vaccines and respiratory therapeutics, all particularly relevant and topical in the environment of heightened awareness of the Coronavirus in 2020. It also has Europe's only commercial 24 bed quarantine clinic and on-site virology laboratory at Queen Mary's Hospital in London.

Additionally, a link to the video of Open Orphan's presentation will be made available on the Company website following the event.

For further information on the Shares Investor Evening, please visit the event website https://www.sharesmagazine.co.uk/events/event/growth-innovation-forum-2020-1

Investor Presentation

A link to our investor presentation is available on our website at https://www.openorphan.com/sites/openorphan/files/Open%20Orphan%20Investor%20Deck_0.pdf.

For further information please contact

 
 
                                                +353 (0)1 644 
 Open Orphan plc                                0007 
  Cathal Friel, Executive Chairman              +44 (0)20 7347 
  Trevor Phillips, Chief Executive Officer      5350 
 
 Arden Partners plc (Nominated Adviser and 
  Joint Broker)                               +44 (0)20 7614 
  John Llewellyn-Lloyd / Benjamin Cryer        5900 
 
 Davy (Euronext Growth Adviser and Joint 
  Broker)                                     +353 (0)1 679 
  Anthony Farrell                              6363 
 
 Camarco (Financial PR) 
                                              +44 (0)20 3757 
 Tom Huddart / Daniel Sherwen                  4980

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

Notes to Editors:

Open Orphan is a rapidly growing European full pharmaceutical services company with a focus on orphan drug and specialist services, comprising two commercial specialist CRO services businesses (Venn and hVIVO) and a developing early stage orphan drug genomics data platform business capturing valuable genetic data from patient populations with specific diseases with designated orphan drug status and incorporating AI tools. In June 2019, Open Orphan acquired AIM-listed Venn Life Sciences Holdings plc in a reverse take-over and in January 2020 it completed the Merger with hVIVO plc. Venn, as an integrated drug development consultancy, offers CMC (chemistry, manufacturing and controls) , preclinical, phase I & II clinical trials design and execution. hVIVO, is a world leader in the provision of viral challenge studies, vaccine and viral laboratory services, supporting product development for customers developing antivirals, vaccines and respiratory therapeutics, all particularly relevant and topical in the environment of heightened awareness of the Coronavirus in 2020. The Merger with hVIVO created a European full pharma services company broadening the Company's customer base and with complementary specialist CRO services, widened the range of the Company's service offerings.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAUPUBPPUPUGMQ

(END) Dow Jones Newswires

February 07, 2020 02:01 ET (07:01 GMT)

Grafico Azioni Hvivo (LSE:HVO)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Hvivo
Grafico Azioni Hvivo (LSE:HVO)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Hvivo